Jacobs & Co. CA Has $7.04 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Jacobs & Co. CA reduced its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,052 shares of the medical instruments supplier's stock after selling 12,760 shares during the period. Jacobs & Co. CA's holdings in Becton, Dickinson and Company were worth $7,044,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $33,000. Tompkins Financial Corp boosted its stake in Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier's stock worth $36,000 after purchasing an additional 46 shares in the last quarter. Sound Income Strategies LLC grew its holdings in shares of Becton, Dickinson and Company by 35.8% during the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier's stock worth $40,000 after purchasing an additional 44 shares during the last quarter. Finally, Abound Wealth Management increased its stake in shares of Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier's stock valued at $46,000 after buying an additional 96 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.3 %

Shares of NYSE:BDX traded down $0.78 during trading on Friday, hitting $233.65. 2,597,939 shares of the company's stock were exchanged, compared to its average volume of 1,896,587. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The firm has a market cap of $67.76 billion, a P/E ratio of 39.34, a PEG ratio of 1.64 and a beta of 0.39. The firm has a 50-day moving average price of $226.91 and a two-hundred day moving average price of $232.45. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $248.42.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion during the quarter, compared to analysts' expectations of $5.38 billion. During the same quarter in the previous year, the company posted $3.42 EPS. The business's revenue for the quarter was up 6.9% compared to the same quarter last year. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.78%. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's dividend payout ratio (DPR) is 70.03%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the completion of the transaction, the executive vice president now owns 16,201 shares of the company's stock, valued at $3,807,235. The trade was a 4.64 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of the firm's stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total value of $633,810.54. Following the sale, the executive vice president now directly owns 6,141 shares in the company, valued at $1,371,469.53. The trade was a 31.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,747 shares of company stock worth $1,949,520. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Citigroup upgraded shares of Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and upped their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Finally, StockNews.com lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $283.50.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.